| Document |
Document Title |
|
WO/2000/059510A1 |
This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula (I), wherein R?1¿, R?2¿ and R?3¿ are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those...
|
|
WO/2000/059901A1 |
This invention relates to compounds formula (I) and pharmaceutically acceptable salts thereof which are inhibitors of protein kinase activity, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these...
|
|
WO/2000/059880A1 |
The present invention relates to cinnamide compounds of formula (I), in which at least one of R¿1? to R¿5? is a '$i(cis)-cinnamide' (a) or a '$i(trans)-cinnamide' (b) and the other variables are as defined in the claims, that are usefu...
|
|
WO2000033839B1 |
Non-peptide compounds that act as antagonists of the intestinal hormone glucagon-like peptide 1 (GLP-1) have a 9H- beta -carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit...
|
|
WO/2000/056718A1 |
Compounds represented by general formula (I) or pharmacologically acceptable salts thereof, wherein Y represents hydrogen, cyano or carbamoyl; Z represents CH or nitrogen; -A-B- represents -CH¿2?-CH¿2?- or -CH=CH-; m is 1 or 2; and n i...
|
|
WO/2000/056726A1 |
A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The a...
|
|
WO/2000/055155A2 |
Heterocyclic compounds of formula (I) wherein B is (1) [wherein R¿1? is hydrogen or lower alkyl; R¿2? is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino (lower) alkyl; A is lower ...
|
|
WO/2000/055152A1 |
Disclosed are novel aromatic heterocyclic compounds of formula (I) wherein Ar¿1?,Ar¿2?,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions. Also disclos...
|
|
WO/2000/053583A1 |
The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
|
|
WO/2000/053591A1 |
The invention relates to thiazolyl urea derivatives of formula (I), to a method for the production thereof, and to their use as medicaments, in particular, as antiviral medicaments.
|
|
WO/2000/052006A1 |
Compounds of formula (I) wherein M is an alkali metal or an alkaline earth metal; n is 1 or 2; r and s, independently of one another, are 0, 1/2, 1, 1,5, 2, 2,5 or 3; and L is ethyl acetate, acetonitrile, dimethylsulfoxide, dimethylforma...
|
|
WO/2000/050386A1 |
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
WO/2000/050406A1 |
The present invention provides the synthesis of heterocyclic compounds based on the isoquinoline ring. More specifically, the invention provides novel isoquinoline derivatives as well as novel libraries comprised of such compouds.
|
|
WO/2000/048993A1 |
The invention provides aminoacid-arylaminoalkylamides in which the C-terminal carboxy group of the amino acid is substituted by an arylaminoalkylamino substituent and in which the amino nitrogen atom of the amino acid forms a peptide or ...
|
|
WO/2000/048974A1 |
The invention relates to a composition of vinyl compounds containing e) at least one polymerisable compound that is provided with at least one O-vinyl group or N-vinyl group and f) at least one ammonium salt of general formula (I) wherei...
|
|
WO/2000/047566A1 |
The invention relates to phenylsulfonyl ureas, to methods for producing them and to their use as herbicides and plant growth regulators. According to the invention, compounds of formula (I) or their salts are suitable for use as herbicid...
|
|
WO/2000/047212A1 |
The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -N...
|
|
WO/2000/047554A2 |
Novel compounds of formula in which A is a substituted or unsubstituted phenyl, naphthyl or monocyclic heterocyclic ring, D is a substituted or unsubstituted phenyl or aromatic six-membered heterocyclic ring, K is a substituted or unsubs...
|
|
WO/2000/047568A2 |
Novel 1,1-dioxido-1,2-benzothiazepines, derivatives and analogs thereof, pharmaceutical compositions containing them, and their use in medicine, particularly in the prophylaxis and/or treatment of hyperlipidemic diseases, conditions and/...
|
|
WO/2000/047553A2 |
Alkenyl and alkynyl compounds as potent and highly selective inhibitors of factor Xa isolated or assembled in the prothrombinase complex and compositions containing such alkenyl and alkynyl compounds are described. Such compounds show se...
|
|
WO/2000/044709A2 |
Compound of the formula (B) are useful in treating disease conditions mediated by TNF-$g(a), such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage l...
|
|
WO/2000/044226A1 |
The invention relates to formulations containing a) at least one ammonium salt of a sulfonylurea, wherein the ammonium cation of the salt has at least one substituent that is not hydrogen, and b) conventional auxiliary agents and additives.
|
|
WO/2000/043366A1 |
Compounds having an antitumor activity and causing no morphological change in cells. Compounds of general formula (I), pharmaceutically acceptable salts of them and solvates thereof, and medicinal compositions containing the same. In for...
|
|
WO/2000/042979A1 |
The invention concerns a composition for oxidation dyeing of keratin fibres, and in particular human keratin fibres such as hair, comprising at least an oxidation base and, as coupler, at least a 2-acylaminophenol of formula (I) comprisi...
|
|
WO/2000/043390A1 |
An antifungal compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: X is CH or N; Y is O, formula (IA) or formula (IB); R?1¿ and R?2¿ are each independently F or Cl; R?3¿ is a thiophenyl, naphthyl, or phenyl ...
|
|
WO/2000/043362A1 |
A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an $i(N)-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT¿2A? receptor and are therefore ...
|
|
WO/2000/041505A2 |
The invention features a compound having the formula (I) below. The invention also relates to a pharmaceutical composition including (a) a compound of formula (I) and (b) a pharmaceutically-acceptable carrier. The invention further relat...
|
|
WO/2000/040536A1 |
Ketoisophorone derivatives represented by general formula (2) are produced by oxidizing a $g(b)-isophorone derivative represented by general formula (1) in the presence of an oxidation catalyst in a solvent substantially free from acid c...
|
|
WO/2000/039087A2 |
This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula (I): wherein X is O, S or NR?1¿ which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition...
|
|
WO/2000/039716A2 |
This invention relates to compounds of formula (1), wherein substituents are defined in the description, that inhibit farnesylation of mutant ras gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The i...
|
|
WO/2000/039119A1 |
Novel compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl-protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. ...
|
|
WO/2000/037459A1 |
Disclosed are compounds of formula (1.0) wherein R?13¿ represents an imidazole ring; R?14¿ represents a carbamate, urea, amide or sulfonamide group; R?8¿ represents H when the alkyl chain between the amide group and the R?13¿ imidazo...
|
|
WO/2000/037458A1 |
Disclosed are compounds of formula (1.0), wherein R?8¿ represents a cyclic moiety to which is bound an imodazolylalkyl group; R?9¿ represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined ...
|
|
WO/2000/037074A1 |
A compound of formula (IA) or (IB) in which R?1¿ is an optionally substituted heteroaryl group which comprises a five membered heteroaromatic ring which has at least one nitrogen atom and which is linked via a nitrogen atom; R?2¿ is vi...
|
|
WO/2000/035916A1 |
The invention relates to compounds of formula (I), wherein R?3¿ represents a 5-membered heteroaromatic ring of formula (II), in which D, E, G and J independently represent CR14¿ or a nitrogen atom, with at least one of D, E, G and J re...
|
|
WO/2000/035858A1 |
The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of formula (I), wherein R?1¿, E, X?1¿ to X?4¿ and G?1¿ and G?2¿ are as defined in the description and the claims, as well as hydrates or solvates a...
|
|
WO/2000/035553A1 |
A method which comprises mixing (1) a solution containing an organic compound which is oleophilic in the range of pH's higher than 2 and an alkoxide of a Group III or IV metal of the short-form Periodic Table with (2) water and (3) a pol...
|
|
WO/2000/035864A1 |
The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the tre...
|
|
WO/2000/034231A1 |
This invention pertains generally to valency molecules, such as valency platform molecules which act as scaffolds to which one or more molecules may be covalently tethered to form a conjugate. More particularly, the present invention per...
|
|
WO/2000/034267A1 |
A process for industrially advantageously producing a compound represented by formula (II) (wherein R?1¿ represents an optionally substituted hydrocarbon group or optionally substituted heterocyclic group; X represents an optionally sub...
|
|
WO/2000/034437A2 |
The present invention is directed to compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds ...
|
|
WO/2000/032577A2 |
Novel compounds of formula (I) in which R, R?1¿ and R?2¿ have the meaning indicated, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
WO/2000/032572A2 |
Arrays of ionic liquids are provided for combinatorial materials science research. These ionic liquids may be characterized by the general formula A?+¿B?-¿ where A?+¿ represents any stable inorganic or organic cation and B?-¿ represe...
|
|
WO/2000/031067A1 |
Propanoic acid derivatives of formula (1) are described: Ar-X?1¿-Ar?1¿-Z-R in which Ar is a nitrogen base containing group; X?1¿ is linker atom or group; Ar?1¿ is an optionally substituted 5- or 6-membered nitrogen-containing aromati...
|
|
WO/2000/031039A1 |
Novel compounds of formula (I), in which R, R?1¿, R?2¿ and i have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
WO/2000/029396A1 |
The invention relates to novel substituted phenyloxazolidone derivatives, to a method for producing them, to pharmaceutical compositions containing them and to their use for producing medicaments, especially for producing antibacterial m...
|
|
WO/2000/027827A1 |
Novel oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds i...
|
|
WO/2000/026192A1 |
The invention relates to novel 2-phenylbenzimidazoles of general formula (I) or (II), wherein the radicals have the meanings cited in the description, and to their tautomeric forms, possible enantiomeric and diastereomeric forms, to thei...
|
|
WO/2000/025780A1 |
The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH media...
|
|
WO/2000/021924A1 |
The invention relates to benzocyclohexandiones of general formula (I), a method for the production and use thereof as herbicides and plant growth regulators. In said general formula (I), R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿ and R?7¿...
|
